Bristol Myers Squibb has announced that the FDA has given approval to label updates for Breyanzi and Abecma to treat multiple myeloma.

On Friday, the United States Department of Agriculture's Food Safety and Inspection Service (FSIS) announced in a report that the company based in Union, New Jersey, is recalling 143,416 pounds of ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

Easy availability online, self-medication, lack of awareness and social media quackery make for a risky drug cocktail ...

The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.

Bristol Myers (BMY) receives FDA approval for label updates for Breyanzi and Abecma, that can ease access to the cancer cell ...

Last week, Kraft Heinz and General Mills said that they would remove artificial dyes from their U.S. products by the end of ...

The Trump administration is continuing to make its imprint on U.S. vaccine policy in recent days. The moves could change what ...

As a new variant that causes 'razor blade throat' spreads, the FDA updates vaccine warnings to include information on heart ...

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and ...

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

The Food and Drug Administration said Wednesday it was expanded existing warnings on the two leading COVID vaccines about a ...